105 related articles for article (PubMed ID: 10675987)
1. First bioanalytical evaluation of nonpeptidic cage dimeric HIV-1 protease inhibitor N-benzyl 4-aryl-1,4-dihydropyridine H17: biotransformation and toxicity on Hep G2 cells.
Hilgeroth A; Langner A
Arch Pharm (Weinheim); 2000 Jan; 333(1):32-4. PubMed ID: 10675987
[TBL] [Abstract][Full Text] [Related]
2. Bioanalysis of syn dimeric HIV-1 protease inhibitor N-benzyl 4-aryl-1,4-dihydropyridine H19: metabolic and cytotoxic properties in Hep G2 cells.
Hilgeroth A; Langner A
Arch Pharm (Weinheim); 2000 Jun; 333(6):195-7. PubMed ID: 10909192
[TBL] [Abstract][Full Text] [Related]
3. Dimeric 4-Aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitors.
Hilgeroth A
Mini Rev Med Chem; 2002 Jun; 2(3):235-45. PubMed ID: 12370065
[TBL] [Abstract][Full Text] [Related]
4. Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study.
Hilgeroth A; Fleischer R; Wiese M; Heinemann FW
J Comput Aided Mol Des; 1999 May; 13(3):233-42. PubMed ID: 10216831
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of the first N-alkyl cage dimeric 4-aryl-1,4-dihydropyridines as novel nonpeptidic HIV-1 protease inhibitors.
Hilgeroth A; Wiese M; Billich A
J Med Chem; 1999 Nov; 42(22):4729-32. PubMed ID: 10579836
[TBL] [Abstract][Full Text] [Related]
6. Cage dimeric N-acyl- and N-acyloxy-4-aryl-1,4-dihydropyridines as first representatives of a novel class of HIV-1 protease inhibitors.
Hilgeroth A; Billich A
Arch Pharm (Weinheim); 1999 Nov; 332(11):380-4. PubMed ID: 10605378
[TBL] [Abstract][Full Text] [Related]
7. Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors.
Hilgeroth A; Billich A
Arch Pharm (Weinheim); 1999 Jan; 332(1):3-5. PubMed ID: 10073137
[No Abstract] [Full Text] [Related]
8. Structure-activity relationships of first bishydroxymethyl-substituted cage dimeric 4-aryl-1,4-dihydropyridines as HIV-1 protease inhibitors.
Hilgeroth A; Lilie H
Eur J Med Chem; 2003 May; 38(5):495-9. PubMed ID: 12767599
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein effects of cyclic urea HIV protease inhibitor DMP 323 in competitional absorption studies.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Arch Pharm (Weinheim); 2006 Nov; 339(11):625-8. PubMed ID: 17048292
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Pharm Res; 2004 Oct; 21(10):1862-6. PubMed ID: 15553233
[TBL] [Abstract][Full Text] [Related]
11. The effect of human immunodeficiency virus-1 protease inhibitors on the toxicity of a variety of cells.
Germinario RJ; Colby-Germinario SP
In Vitro Cell Dev Biol Anim; 2003; 39(7):275-9. PubMed ID: 14561112
[TBL] [Abstract][Full Text] [Related]
12. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Fitzsimmons ME; Collins JM
Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation and toxicity of the lipoxygenase inhibitor 2-hydroxy-5-methyllaurophenone oxime (FLM 5011) on Hep G2 cells.
Mühlenfeld K; Langner A
Arch Pharm (Weinheim); 1998; 331(7-8):259-61. PubMed ID: 9747183
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.
Thaisrivongs S; Watenpaugh KD; Howe WJ; Tomich PK; Dolak LA; Chong KT; Tomich CC; Tomasselli AG; Turner SR; Strohbach JW
J Med Chem; 1995 Sep; 38(18):3624-37. PubMed ID: 7658450
[TBL] [Abstract][Full Text] [Related]
16. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.
Otto MJ; Garber S; Winslow DL; Reid CD; Aldrich P; Jadhav PK; Patterson CE; Hodge CN; Cheng YS
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7543-7. PubMed ID: 8356053
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and activity of N-benzyl pseudopeptides HIV protease inhibitors.
Marastoni M; Bazzaro M; Bortolotti F; Tomatis R
Bioorg Med Chem; 2003 May; 11(11):2477-83. PubMed ID: 12735995
[TBL] [Abstract][Full Text] [Related]
18. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
Luna B; Townsend MU
Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
Skulnick HI; Johnson PD; Aristoff PA; Morris JK; Lovasz KD; Howe WJ; Watenpaugh KD; Janakiraman MN; Anderson DJ; Reischer RJ; Schwartz TM; Banitt LS; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Dolak LA; Seest EP; Schwende FJ; Rush BD; Howard GM; Toth LN; Wilkinson KR; Romines KR
J Med Chem; 1997 Mar; 40(7):1149-64. PubMed ID: 9089336
[TBL] [Abstract][Full Text] [Related]
20. Probe detects HIV protease and toxicity of drugs.
AIDS Patient Care STDS; 2010 Nov; 24(11):744. PubMed ID: 21067358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
